There have been several studies that show no increased risk for differentiated thyroid cancer, but some of the most recent studies metanalyses of randomized control trials of GLP-1 agonists vs
At 5 mg, that is 50 units
If a figure or equation is essential, please include within the text of the eLetter a link to the figure, equation, or full text with special characters at a public repository with versioning, such as Zenodo
The guide on four weeks on semaglutide with no weight loss specifically addresses early non-response, while tirzepatide not working anymore addresses the scenario where effects diminish over time
The longest cardiovascular outcome trials follow patients for around 5 to 6 years and show consistent cardiovascular benefit and acceptable tolerability
This is not marketing hype